Department of Gynecological Oncology, Norfolk and Norwich University Hospital, NHS Trust, Norwich, UK.
Gynecologic Oncology Unit, La Paz University Hospital, IdiPAZ, Madrid, Spain.
Arch Gynecol Obstet. 2018 Aug;298(2):373-380. doi: 10.1007/s00404-018-4820-7. Epub 2018 Jun 26.
To investigate differences and similarities in the clinical approach of young clinicians managing women with endometrial cancer (EC) conservatively.
A web-based survey was carried out. A platform of the European Network of Young Gynaecological Oncologists (ENYGO) database was used. A 38-item multiple-choice questionnaire was used to evaluate current practice in fertility-sparing management of EC. The survey covered investigations, treatment options, follow-up and management of recurrence and future family planning. Descriptive statistics were used.
Overall, 116 out of 650 (17.84%) ENYGO members responded to the survey. In 92 (79.3%) centres, the caseload of early stage EC treated conservatively was less than 10 per year. One hundred and seven responders (93.8%) believe that treatment with progestins could be offered in grade 1 EC without myometrial invasion, but a minority would recommend it even for grade 2 tumours with no myometrial invasion or grade 1 with superficial invasion. The diagnostic tool for establishing grade of tumour was hysteroscopy with dilatation and curettage in 64 (55%) centres. Medroxyprogesterone acetate represents the most commonly prescribed progestogen (55, 47.4%). In 78 (67.2%) centres, a repeat endometrial biopsy was offered after 3 months of treatment commencement. Recurrences are treated mostly with hysterectomy (81, 69.9%) with only a small number of responders recommending to repeat progestin treatment. Lynch syndrome is a contraindication for conservative management in half of the responders (57, 49.1%). Most clinicians agree that patients should be referred promptly for assisted reproductive techniques once complete response has been achieved (68, 58.6%).
Our study shows that conservative management is increasingly offered to women affected by early stage EC wishing to preserve their fertility. Further studies and joint registries are required to evaluate safety and effectiveness of this approach in this probably growing number of patients.
研究年轻临床医生在保守治疗子宫内膜癌(EC)的女性时临床方法的异同。
进行了一项基于网络的调查。使用欧洲青年妇科肿瘤学家网络(ENYGO)数据库平台。使用 38 项多项选择题问卷评估 EC 保留生育力管理的当前实践。该调查涵盖了调查、治疗选择、随访和复发管理以及未来的计划生育。使用描述性统计。
总体而言,在 650 名 ENYGO 成员中,有 116 名(17.84%)对调查做出了回应。在 92 个(79.3%)中心,每年保守治疗早期 EC 的病例数少于 10 例。107 名应答者(93.8%)认为可以在无肌层浸润的 1 级 EC 中使用孕激素治疗,但少数人甚至会推荐无肌层浸润的 2 级肿瘤或 1 级伴浅层浸润的肿瘤使用孕激素治疗。64 个(55%)中心将宫腔镜检查联合扩张刮宫术作为肿瘤分级的诊断工具。醋酸甲羟孕酮是最常用的孕激素(55,47.4%)。在 78 个(67.2%)中心,在开始治疗后 3 个月提供重复子宫内膜活检。复发大多采用子宫切除术治疗(81,69.9%),只有少数应答者建议重复孕激素治疗。半数应答者(57,49.1%)认为 Lynch 综合征是保守治疗的禁忌症。大多数临床医生认为,一旦完全缓解,应尽快将患者转介进行辅助生殖技术(68,58.6%)。
我们的研究表明,越来越多的早期 EC 患者希望保留生育能力,因此选择保守治疗。需要进一步的研究和联合登记来评估这种方法在这个可能不断增加的患者群体中的安全性和有效性。